Cardiologia Croatica, Vol. 11 No. 7, 2016.
Pregledni rad
https://doi.org/10.15836/ccar2016.285
Cardiovascular Safety of Oral Antidiabetic Drugs.
Luka Zaputović
orcid.org/0000-0001-9415-9618
; Medicinski fakultet Sveučilišta u Rijeci, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Željka Rubeša Miculinić
; Medicinski fakultet Sveučilišta u Rijeci, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Sanja Matijević Rončević
orcid.org/0000-0003-0627-2114
; Medicinski fakultet Sveučilišta u Rijeci, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
David Gobić
orcid.org/0000-0001-9406-1127
; Medicinski fakultet Sveučilišta u Rijeci, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Teodora Zaninović Jurjević
; Medicinski fakultet Sveučilišta u Rijeci, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Sažetak
Croatia belongs to a group of European countries with a high cardiovascular risk and growing prevalence of diabetes mellitus type 2 (DMT2). According to data of the National Diabetes Registry (CroDiab registry), a total of 254,296 individuals aged >18 suffering from diabetes were registered in 2014 (7.9%). Along with hypertension and hyperlipidemia, DMT2 is one of the leading cardiovascular risk factors. Prompted by adverse cardiovascular effects of rosiglitazone, demonstrated in the RECORD study and subsequent meta-analyses, the main drug regulatory agencies require clinical trials of the effect on cardiovascular outcomes and safety evidence for all antidiabetic drugs. On assessing the effects of antidiabetic drugs on cardiovascular risk, the two-sided confidence interval upper borderline value of 95% (95% CI) is highly relevant for the estimated risk ratio. Additional safety testing is required for all antidiabetic drugs with the risk ratio upper limit ≥1.3. Cardiovascular safety of oral antidiabetic drugs is of special importance in patients with heart failure. Considering the great number of antidiabetic drugs on the market, decision on optimal DMT2 therapy should be made in dependence of specific characteristics of each individual patient and cardiovascular risk assessment.
Ključne riječi
diabetes mellitus; oral anti diabetic drugs; cardiovascular diseases
Hrčak ID:
161133
URI
Datum izdavanja:
30.6.2016.
Posjeta: 2.340 *